JP2009538269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538269A5 JP2009538269A5 JP2009500480A JP2009500480A JP2009538269A5 JP 2009538269 A5 JP2009538269 A5 JP 2009538269A5 JP 2009500480 A JP2009500480 A JP 2009500480A JP 2009500480 A JP2009500480 A JP 2009500480A JP 2009538269 A5 JP2009538269 A5 JP 2009538269A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- 2mepe
- glycyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 13
- 239000011859 microparticle Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- SLQBBGFTXIRLLR-SDBXPKJASA-N (4S)-4-amino-5-[(2S)-1-(2-aminoacetyl)-2-methylpyrrolidine-2-carbonyl]oxy-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](N)C(=O)OC(=O)[C@]1(C)CCCN1C(=O)CN SLQBBGFTXIRLLR-SDBXPKJASA-N 0.000 claims 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- JJGBXTYGTKWGAT-YUMQZZPRSA-N Gly-Pro-Glu Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O JJGBXTYGTKWGAT-YUMQZZPRSA-N 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 230000007515 enzymatic degradation Effects 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000012071 phase Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 1
- 235000011069 sorbitan monooleate Nutrition 0.000 claims 1
- 229940035049 sorbitan monooleate Drugs 0.000 claims 1
- 239000001593 sorbitan monooleate Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- BUSXWGRAOZQTEY-SDBXPKJASA-N trofinetide Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@]1(C)CCCN1C(=O)CN BUSXWGRAOZQTEY-SDBXPKJASA-N 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78214806P | 2006-03-14 | 2006-03-14 | |
| US60/782,148 | 2006-03-14 | ||
| PCT/US2007/006528 WO2007106555A2 (en) | 2006-03-14 | 2007-03-14 | Oral formulations of glycyl-2-methylprolyl-glutamate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538269A JP2009538269A (ja) | 2009-11-05 |
| JP2009538269A5 true JP2009538269A5 (https=) | 2010-05-06 |
| JP5220724B2 JP5220724B2 (ja) | 2013-06-26 |
Family
ID=38510089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500480A Expired - Fee Related JP5220724B2 (ja) | 2006-03-14 | 2007-03-14 | グリシル−２−メチルプロリルグルタミン酸塩の経口製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US7887839B2 (https=) |
| EP (1) | EP2001400B1 (https=) |
| JP (1) | JP5220724B2 (https=) |
| ES (1) | ES2487493T3 (https=) |
| WO (1) | WO2007106555A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007106555A2 (en) * | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
| EP2349209A2 (en) * | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| ES2386177B1 (es) * | 2010-09-21 | 2013-09-23 | Lipotec, S.A. | Nanocapsulas conteniendo microemulsiones |
| AU2012209466C1 (en) | 2011-01-27 | 2016-06-23 | Neuren Pharmaceuticals Limited | Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| CA2929286A1 (en) * | 2012-11-28 | 2014-06-05 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| EP3024463B1 (en) * | 2013-07-25 | 2020-03-25 | Neuren Pharmaceuticals Limited | Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| KR101695335B1 (ko) | 2014-11-14 | 2017-01-11 | 한국기계연구원 | 코어-쉘 나노입자 |
| KR20220059479A (ko) * | 2019-08-05 | 2022-05-10 | 뉴렌 파마슈티컬즈 리미티드 | 트로피네타이드의 조성물 |
| BR102020010237A2 (pt) * | 2020-05-22 | 2021-12-07 | Ouro Fino Saúde Animal Ltda | Plataforma para mascaramento de sabor |
| MX2023014655A (es) | 2021-07-12 | 2024-01-12 | Acadia Pharm Inc | Formas cristalinas de trofinetida. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824638A (en) * | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US7112570B2 (en) * | 2000-08-24 | 2006-09-26 | Neuren Pharmaceuticals, Ltd. | GPE analogs |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| AUPR289601A0 (en) * | 2001-02-05 | 2001-03-01 | Commonwealth Scientific And Industrial Research Organisation | Method of tissue repair |
| ATE435852T1 (de) * | 2001-05-24 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Gpe-analoga und peptidomimetika |
| US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| GB0307428D0 (en) * | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| WO2005097161A2 (en) * | 2004-03-30 | 2005-10-20 | Neuren Pharmaceuticals Limited | Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury |
| EP1888618A4 (en) * | 2005-05-23 | 2009-07-15 | Neuren Pharmaceuticals Ltd | Analogs of glycyl-prolyl-glutamate |
| WO2007106555A2 (en) * | 2006-03-14 | 2007-09-20 | Neuren Pharmaceuticals Limited | Oral formulations of glycyl-2-methylprolyl-glutamate |
-
2007
- 2007-03-14 WO PCT/US2007/006528 patent/WO2007106555A2/en not_active Ceased
- 2007-03-14 EP EP07753175.4A patent/EP2001400B1/en not_active Not-in-force
- 2007-03-14 JP JP2009500480A patent/JP5220724B2/ja not_active Expired - Fee Related
- 2007-03-14 ES ES07753175.4T patent/ES2487493T3/es active Active
-
2008
- 2008-09-15 US US12/283,684 patent/US7887839B2/en active Active
-
2011
- 2011-02-14 US US13/026,787 patent/US8178125B2/en active Active
-
2012
- 2012-05-14 US US13/471,150 patent/US8496963B2/en active Active